Corvin, A., Donohoe, G., McGhee, K. A., Murphy, K., Kenny, N., Schwaiger, S., Nangle, J. M., Morris, D. and Gill, M., 2007. D-amino acid oxidase (DAO) genotype and mood symptomatology in schizophrenia. Neuroscience Letters, 426 (2), pp. 97-100.
Full text not available from this repository.
A series of genetic studies have identified the D-amino acid oxidase (DAO) gene as potentially contributing to schizophrenia susceptibility. An interacting gene, D-amino acid oxidase activator (DAOA) has also been implicated and it has been suggested that variation at these genes may influence the efficiency of glutamate gating at N-methyl-D-aspartate-type (NMDA) receptors. However, recent data suggests that DAOA may influence susceptibility to mood episodes across the spectrum of psychotic disorders rather than contributing to a specific psychosis phenotype. The aim of this study was to determine whether risk variation at DAO is similarly associated with affective or other clinical symptoms in psychosis. We have previously reported association between risk variation at DAO and schizophrenia in an Irish case-control sample. In this study we investigated the relationship between a defined genetic risk variant at DAO and PANSS-derived clinical symptom factors in a sample of 249 patients using principal component and Kruskal-Wallis analyses. Carriers of the DAO risk variant scored significantly higher on the 'depression/anxiety' factor than non-carriers (H=9.02, d.f.=2, p=0.01). These data suggest a potential role for DAO in susceptibility to depressive symptoms in schizophrenia, but a more general role for DAO in affective disorders cannot be excluded.
|Uncontrolled Keywords:||Psychosis; Depression/anxiety; Susceptibility genes; DAO|
|Subjects:||Technology > Medicine and Health|
|Group:||School of Health and Social Care|
|Deposited By:||Dr Kevin McGhee|
|Deposited On:||04 May 2010 20:32|
|Last Modified:||07 Mar 2013 15:27|
|Repository Staff Only -|
|BU Staff Only -|
|Help Guide -||Editing Your Items in BURO|